{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:42:57Z","timestamp":1792449777035,"version":"4.5.0"},"reference-count":123,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Asthma is a common disease affecting 350 million people worldwide, which is characterized by airways inflammation and hyperreactivity. Historically diagnosis and treatment have been mainly based on symptoms, which have the potential to result in misdiagnosis and inappropriate treatment. Nitric oxide (NO) is exhaled in human breath and is a marker of airways inflammation. Levels of NO are increased in the exhaled breath of patients with type 2 asthma and fractional exhaled nitric oxide (FeNO) provides an objective biomarker of airway inflammation. FeNO testing is an accessible, noninvasive, and easy-to-use test. Cut-off values have been established by the American Thoracic Society (ATS), the Global Initiative for Asthma (GINA), and the National Institute for Health and Care Excellence (NICE) but vary between guidance. FeNO levels have been shown to be predictive of blood and sputum eosinophil levels but should not be used in isolation and current guidance emphasizes the importance of incorporating clinical symptoms and testing when utilizing FeNO results. The inclusion of FeNO testing can increase diagnostic accuracy of asthma, while high levels in asthmatic patients can help predict response to inhaled corticosteroids (ICS) and suppression of levels with ICS to monitor adherence. FeNO levels are also a predictor of asthma risk with increased exacerbation rates and accelerated decline in lung function associated with high levels as well as having an emerging role in predicting response to some biologic therapies in severe asthma. FeNO testing is cost-effective and has been shown, when combined with clinical assessment, to improve asthma management.<\/jats:p>","DOI":"10.1055\/s-0042-1743290","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:08:24Z","timestamp":1646636904000},"page":"635-645","source":"Crossref","is-referenced-by-count":94,"title":["FeNO in Asthma"],"prefix":"10.1055","volume":"43","author":[{"given":"Lola","family":"Loewenthal","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, London, United Kingdom"},{"name":"National Heart and Lung Institute, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Menzies-Gow","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Royal Brompton and Harefield Hospitals, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"issue":"09","key":"ref2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(17)30293-X","article-title":"Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"5","author":"GBD 2015 Chronic Respiratory Disease Collaborators","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1183\/20734735.0362-2018","article-title":"Over- and under-diagnosis in asthma","volume":"15","author":"J Kavanagh","year":"2019","journal-title":"Breathe (Sheff)"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jama.2016.19627","article-title":"Reevaluation of diagnosis in adults with physician-diagnosed asthma","volume":"317","author":"S D Aaron","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"ref6","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1503\/cmaj.081332","article-title":"Overdiagnosis of asthma in obese and nonobese adults","volume":"179","author":"S D Aaron","year":"2008","journal-title":"CMAJ"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.4104\/pcrj.2012.00057","article-title":"A cross-sectional study of patterns of airway dysfunction, symptoms and morbidity in primary care asthma","volume":"21","author":"D Shaw","year":"2012","journal-title":"Prim Care Respir J"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2466-11-27","article-title":"(Correcting) misdiagnoses of asthma: a cost effectiveness analysis","volume":"11","author":"S Pakhale","year":"2011","journal-title":"BMC Pulm Med"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1378\/chest.10-2794","article-title":"Predictors of symptoms are different from predictors of severe exacerbations from asthma in children","volume":"140","author":"A C Wu","year":"2011","journal-title":"Chest"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(16)31399-X","article-title":"Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study","volume":"389","author":"H K Reddel","year":"2017","journal-title":"Lancet"},{"issue":"145","key":"ref11","doi-asserted-by":"crossref","first-page":"170064","DOI":"10.1183\/16000617.0064-2017","article-title":"Personalised medicine in asthma: time for action: Number 1 in the Series \u201cPersonalised medicine in respiratory diseases\u201d edited by Renaud Louis and Nicolas Roche","volume":"26","author":"K F Chung","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"S E Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1164\/rccm.201611-2232PP","article-title":"Eosinophilic and noneosinophilic asthma","volume":"197","author":"T F Carr","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(17)30879-6","article-title":"After asthma: redefining airways diseases","volume":"391","author":"I D Pavord","year":"2018","journal-title":"Lancet"},{"issue":"07","key":"ref15","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1172\/JCI84144","article-title":"Current concepts of severe asthma","volume":"126","author":"A Ray","year":"2016","journal-title":"J Clin Invest"},{"issue":"01","key":"ref16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2013present in most, absent in many","volume":"15","author":"J V Fahy","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"25","key":"ref17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1126\/sciimmunol.aat1604","article-title":"Type 2 immunity: expanding our view","volume":"3","author":"C M Lloyd","year":"2018","journal-title":"Sci Immunol"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"P G Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref19","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"M Humbert","year":"2005","journal-title":"Allergy"},{"issue":"13","key":"ref20","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"H G Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"J M FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"ref22","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"M Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"Ab381","DOI":"10.1016\/j.jaci.2014.12.1874","article-title":"Reslizumab treatment for moderate to severe asthma with elevated blood eosinophil levels","volume":"135","author":"M Castro","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"A Papi","year":"2018","journal-title":"Lancet"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jaci.2010.03.026","article-title":"Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma","volume":"126","author":"N S Kulkarni","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/rcmb.2016-0141PS","article-title":"Emergence of biomolecular pathways to define novel asthma phenotypes. Type-2 immunity and beyond","volume":"55","author":"S E Wenzel","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13223-017-0219-4","article-title":"Asthma biomarkers in the age of biologics","volume":"13","author":"H Kim","year":"2017","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"14","key":"ref28","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1042\/CS20160253","article-title":"Pathogenesis of asthma: implications for precision medicine","volume":"131","author":"R J Russell","year":"2017","journal-title":"Clin Sci (Lond)"},{"issue":"05","key":"ref29","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"R A Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"09","key":"ref30","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/thx.2003.014894","article-title":"Epithelial inducible nitric oxide synthase activity is the major determinant of nitric oxide concentration in exhaled breath","volume":"59","author":"C Lane","year":"2004","journal-title":"Thorax"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jaci.2020.03.006","article-title":"2020 updated asthma guidelines: clinical utility of fractional exhaled nitric oxide (FENO) in asthma management","volume":"146","author":"B Lipworth","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s004080000064","article-title":"High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy","volume":"179","author":"M Ozkan","year":"2001","journal-title":"Lung"},{"issue":"19","key":"ref34","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"A Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"ref35","doi-asserted-by":"crossref","first-page":"9265","DOI":"10.1073\/pnas.84.24.9265","article-title":"Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide","volume":"84","author":"L J Ignarro","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/333664a0","article-title":"Vascular endothelial cells synthesize nitric oxide from L-arginine","volume":"333","author":"R M Palmer","year":"1988","journal-title":"Nature"},{"issue":"S 02","key":"ref37","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.33549\/physiolres.933673","article-title":"Physiology of nitric oxide in the respiratory system","volume":"66","author":"M Antosova","year":"2017","journal-title":"Physiol Res"},{"issue":"21","key":"ref38","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1056\/NEJMoa043596","article-title":"Use of exhaled nitric oxide measurements to guide treatment in chronic asthma","volume":"352","author":"A D Smith","year":"2005","journal-title":"N Engl J Med"},{"issue":"03","key":"ref39","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/thx.51.3.233","article-title":"Exhaled nitric oxide: a new lung function test","volume":"51","author":"P J Barnes","year":"1996","journal-title":"Thorax"},{"issue":"11","key":"ref40","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/0006-2952(89)90403-6","article-title":"Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication","volume":"38","author":"S Moncada","year":"1989","journal-title":"Biochem Pharmacol"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.iac.2018.06.001","article-title":"Exhaled nitric oxide: an update","volume":"38","author":"F CL Hoyte","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"issue":"17","key":"ref42","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.92.17.7809","article-title":"Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo","volume":"92","author":"F H Guo","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"03","key":"ref43","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/0006-291X(90)91583-E","article-title":"Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages","volume":"172","author":"M Di Rosa","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"ref44","doi-asserted-by":"crossref","first-page":"10043","DOI":"10.1073\/pnas.87.24.10043","article-title":"Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells","volume":"87","author":"M W Radomski","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"02","key":"ref45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/thorax.58.2.175","article-title":"Multiple roles of nitric oxide in the airways","volume":"58","author":"F LM Ricciardolo","year":"2003","journal-title":"Thorax"},{"issue":"11","key":"ref46","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1096\/fasebj.12.11.929","article-title":"Increased formation of the potent oxidant peroxynitrite in the airways of asthmatic patients is associated with induction of nitric oxide synthase: effect of inhaled glucocorticoid","volume":"12","author":"D Saleh","year":"1998","journal-title":"FASEB J"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1152\/physrev.00034.2003","article-title":"Nitric oxide in health and disease of the respiratory system","volume":"84","author":"F L Ricciardolo","year":"2004","journal-title":"Physiol Rev"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1164\/ajrccm.153.1.8542105","article-title":"Inhaled nitric oxide. A bronchodilator in mild asthmatics with methacholine-induced bronchospasm","volume":"153","author":"R M Kacmarek","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"issue":"02","key":"ref49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0014-2999(92)90676-U","article-title":"Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans","volume":"210","author":"M G Belvisi","year":"1992","journal-title":"Eur J Pharmacol"},{"issue":"24","key":"ref50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/jci.insight.131733","article-title":"L-Citrulline increases nitric oxide and improves control in obese asthmatics","volume":"4","author":"F Holguin","year":"2019","journal-title":"JCI Insight"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/thx.51.2.218","article-title":"NO or no NO in asthma?","volume":"51","author":"P J Barnes","year":"1996","journal-title":"Thorax"},{"issue":"07","key":"ref52","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1399-3038.2009.00853.x","article-title":"Comparability of a hand-held nitric oxide analyser with online and offline chemiluminescence-based nitric oxide measurement","volume":"20","author":"B Schiller","year":"2009","journal-title":"Pediatr Allergy Immunol"},{"issue":"04","key":"ref53","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1164\/rccm.201806-1182OC","article-title":"Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma","volume":"199","author":"L G Heaney","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"03","key":"ref54","doi-asserted-by":"crossref","first-page":"1901633","DOI":"10.1183\/13993003.01633-2019","article-title":"Clinical utility of fractional exhaled nitric oxide in severe asthma management","volume":"55","author":"A Menzies-Gow","year":"2020","journal-title":"Eur Respir J"},{"issue":"08","key":"ref55","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.rmed.2019.07.010","article-title":"Scottish consensus statement on the role of FeNO in adult asthma","volume":"155","author":"C R Kuo","year":"2019","journal-title":"Respir Med"},{"issue":"01","key":"ref57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of severe asthma: a European Respiratory Society\/American Thoracic Society guideline","volume":"55","author":"F Holguin","year":"2020","journal-title":"Eur Respir J"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S2213-2600(17)30424-1","article-title":"Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial","volume":"6","author":"D B Price","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/cpt.136","article-title":"Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization","volume":"98","author":"S Amur","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40733-018-0047-4","article-title":"Biomarkers in asthma: state of the art","volume":"4","author":"A Tiotiu","year":"2018","journal-title":"Asthma Res Pract"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/cea.12880","article-title":"Revisiting Type 2-high and Type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"D Robinson","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1164\/ajrccm.154.2.8756799","article-title":"Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements","volume":"154","author":"E Pizzichini","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1s","DOI":"10.1183\/09031936.02.00000102","article-title":"Standardised methodology of sputum induction and processing","volume":"37","author":"R Djukanovi\u0107","year":"2002","journal-title":"Eur Respir J Suppl"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fped.2018.00196","article-title":"Measuring airway inflammation in asthmatic children","volume":"6","author":"L Tenero","year":"2018","journal-title":"Front Pediatr"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1183\/09031936.00012415","article-title":"Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes","volume":"46","author":"G A Westerhof","year":"2015","journal-title":"Eur Respir J"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.jaci.2017.04.047","article-title":"Obesity's effect on asthma extends to diagnostic criteria","volume":"141","author":"N Lugogo","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1164\/rccm.201207-1270OC","article-title":"An association between L-arginine\/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype","volume":"187","author":"F Holguin","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1164\/ajrccm.164.8.2101145","article-title":"Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone","volume":"164","author":"D N Payne","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ref69","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201204-0587OC","article-title":"The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma","volume":"186","author":"D M McNicholl","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref70","doi-asserted-by":"crossref","first-page":"e000151","DOI":"10.1136\/bmjresp-2016-000151","article-title":"Effect of inhaled corticosteroids on blood eosinophil count in steroid-na\u00efve patients with COPD","volume":"3","author":"J L Kreindler","year":"2016","journal-title":"BMJ Open Respir Res"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/iid3.166","article-title":"A trial of oral corticosteroids for persistent systemic and airway inflammation in severe asthma","volume":"5","author":"K Oishi","year":"2017","journal-title":"Immun Inflamm Dis"},{"issue":"04","key":"ref72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1183\/13993003.00965-2016","article-title":"A European Respiratory Society technical standard: exhaled biomarkers in lung disease","volume":"49","author":"I Horv\u00e1th","year":"2017","journal-title":"Eur Respir J"},{"issue":"06","key":"ref73","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaci.2005.03.020","article-title":"Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years","volume":"115","author":"F Buchvald","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"07","key":"ref74","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.rmed.2008.02.012","article-title":"Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height","volume":"102","author":"H Dressel","year":"2008","journal-title":"Respir Med"},{"issue":"08","key":"ref75","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/thx.52.8.697","article-title":"Effect of measurement conditions on measured levels of peak exhaled nitric oxide","volume":"52","author":"C A Byrnes","year":"1997","journal-title":"Thorax"},{"issue":"06","key":"ref76","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1378\/chest.12-1310","article-title":"Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial","volume":"142","author":"W J Anderson","year":"2012","journal-title":"Chest"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jaci.2013.12.1070","article-title":"Exhaled nitric oxide: a biomarker integrating both lung function and airway inflammation changes","volume":"134","author":"A Haccuria","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"02","key":"ref78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/thoraxjnl-2016-208704","article-title":"Accuracy of FENO for diagnosing asthma: a systematic review","volume":"72","author":"S Karrasch","year":"2017","journal-title":"Thorax"},{"issue":"10","key":"ref79","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"W W Busse","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2018.08.005","article-title":"Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function","volume":"143","author":"A H Mansur","year":"2018","journal-title":"Respir Med"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/13993003.00699-2016","article-title":"Predictive value of exhaled nitric oxide in the management of asthma: a systematic review","volume":"48","author":"L Lehtim\u00e4ki","year":"2016","journal-title":"Eur Respir J"},{"issue":"04","key":"ref82","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jaci.2013.06.007","article-title":"Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects","volume":"132","author":"A Malinovschi","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jaip.2020.03.038","article-title":"Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma","volume":"8","author":"R Buhl","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"08","key":"ref84","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/cea.13137","article-title":"Simultaneously elevated FeNO and blood eosinophils relate to asthma morbidity in asthmatics from NHANES 2007-12","volume":"48","author":"I Mogensen","year":"2018","journal-title":"Clin Exp Allergy"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4168\/aair.2015.7.4.339","article-title":"The association of lung function, bronchial hyperresponsiveness, and exhaled nitric oxide differs between atopic and non-atopic asthma in children","volume":"7","author":"E Shim","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"issue":"06","key":"ref86","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3109\/02770903.2013.792349","article-title":"Fractional exhaled nitric oxide has a good correlation with asthma control and lung function in Latino children with asthma","volume":"50","author":"M Soto-Ramos","year":"2013","journal-title":"J Asthma"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1183\/13993003.01785-2017","article-title":"Predictors of accelerated decline in lung function in adult-onset asthma","volume":"51","author":"H Coumou","year":"2018","journal-title":"Eur Respir J"},{"issue":"03","key":"ref88","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.alit.2015.12.006","article-title":"Persistently high exhaled nitric oxide and loss of lung function in controlled asthma","volume":"65","author":"K Matsunaga","year":"2016","journal-title":"Allergol Int"},{"issue":"05","key":"ref89","doi-asserted-by":"crossref","first-page":"100544","DOI":"10.1016\/j.waojou.2021.100544","article-title":"Bronchodilator response and lung function decline: associations with exhaled nitric oxide with regard to sex and smoking status","volume":"14","author":"E Nerpin","year":"2021","journal-title":"World Allergy Organ J"},{"issue":"12","key":"ref90","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/thoraxjnl-2018-211540","article-title":"Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis","volume":"73","author":"H L Petsky","year":"2018","journal-title":"Thorax"},{"issue":"01","key":"ref91","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"L G Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","article-title":"The prevalence of severe refractory asthma","volume":"135","author":"P-PW Hekking","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1081-1206(10)63001-3","article-title":"Nonadherence in asthmatic patients: is there a solution to the problem?","volume":"79","author":"B Bender","year":"1997","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1183\/13993003.02259-2019","article-title":"Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma","volume":"55","author":"G d'Ancona","year":"2020","journal-title":"Eur Respir J"},{"issue":"06","key":"ref95","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jaci.2011.09.011","article-title":"Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence","volume":"128","author":"L K Williams","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"06","key":"ref96","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma","volume":"204","author":"S Couillard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"07","key":"ref97","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/02770903.2014.906607","article-title":"The relationship between asthma, asthma control and economic outcomes in the United States","volume":"51","author":"P W Sullivan","year":"2014","journal-title":"J Asthma"},{"issue":"02","key":"ref98","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1398-9995.2006.01254.x","article-title":"Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma","volume":"62","author":"S D Sullivan","year":"2007","journal-title":"Allergy"},{"issue":"02","key":"ref99","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.alit.2019.01.004","article-title":"Biological treatments for severe asthma: a major advance in asthma care","volume":"68","author":"W W Busse","year":"2019","journal-title":"Allergol Int"},{"key":"ref100","volume-title":"Omalizumab for treating severe persistent allergic asthma","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"issue":"08","key":"ref101","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"N A Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"T B Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"I D Pavord","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"ref104","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"P Haldar","year":"2009","journal-title":"N Engl J Med"},{"issue":"06","key":"ref105","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jaci.2017.10.005","article-title":"Biomarkers for severe eosinophilic asthma","volume":"140","author":"S W Yancey","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"ref106","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"R Shrimanker","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between FENO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"A P Hearn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"04","key":"ref108","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"B N Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/JAA.S52387","article-title":"Dupilumab: a novel treatment for asthma","volume":"7","author":"A Vatrella","year":"2014","journal-title":"J Asthma Allergy"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"S Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"26","key":"ref111","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"K F Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"ref112","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"J Corren","year":"2017","journal-title":"N Engl J Med"},{"key":"ref113","first-page":"91","article-title":"Socioeconomic costs of asthma in the European Union, United States and Canada: a systematic review","volume":"91","author":"J Puig-Junoy","year":"2017","journal-title":"Rev Esp Salud P\u00fablica"},{"key":"ref114","volume-title":"Diagnostics Guidance","author":"National Institute for Health and Care Excellence (NICE)","year":"2014"},{"issue":"06","key":"ref115","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.anai.2014.06.013","article-title":"Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic","volume":"113","author":"C LaForce","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"05","key":"ref116","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2500\/aap.2018.39.4165","article-title":"Cost impact of monitoring exhaled nitric oxide in asthma management","volume":"39","author":"R J Arnold","year":"2018","journal-title":"Allergy Asthma Proc"},{"issue":"07","key":"ref117","first-page":"34","article-title":"A review of the utility and cost effectiveness of monitoring fractional exhaled nitric oxide (FeNO) in asthma management","volume":"27","author":"R J Arnold","year":"2018","journal-title":"Manag Care"},{"issue":"03","key":"ref118","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jaci.2014.07.016","article-title":"Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: a cluster-randomized trial in primary care","volume":"135","author":"P J Honkoop","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"07","key":"ref119","first-page":"42","article-title":"Cost-effectiveness analysis of monitoring fractional exhaled nitric oxide (FeNO) in the management of asthma","volume":"27","author":"E A Brooks","year":"2018","journal-title":"Manag Care"},{"issue":"03","key":"ref120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1398-9995.2008.01855.x","article-title":"An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom","volume":"64","author":"D Price","year":"2009","journal-title":"Allergy"},{"issue":"01","key":"ref121","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S2213-2600(17)30429-0","article-title":"FeNO and suspected asthma: better to identify responsiveness to treatment than to label with a diagnosis","volume":"6","author":"K Alving","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref123","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1183\/09031936.00161011","article-title":"Age- and height-based prediction bias in spirometry reference equations","volume":"40","author":"P H Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"02","key":"ref124","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/thoraxjnl-2015-207326","article-title":"Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)","volume":"71","author":"L G Heaney","year":"2016","journal-title":"Thorax"},{"key":"ref125","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.congress-2020.2689","volume-title":"FeNO Testing for Asthma Diagnosis in Primary Care","author":"J Longstaff","year":"2020"},{"issue":"04","key":"ref126","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1034\/j.1399-3003.1999.14d28.x","article-title":"Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis","volume":"14","author":"C Gratziou","year":"1999","journal-title":"Eur Respir J"},{"issue":"02","key":"ref127","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0194599812442322","article-title":"Exhaled nitric oxide measurement in patients affected by nasal polyposis","volume":"147","author":"J Galli","year":"2012","journal-title":"Otolaryngol Head Neck Surg"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1743290.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T23:49:23Z","timestamp":1665532163000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1743290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":123,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2022,10,11]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1743290","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]}}}